Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted therapy for hematologic malignancies.

Philip Kuriakose1

  • 1Department of Internal Medicine, Division of Hematology/Oncology, Henry Ford Hospital, Detroit, MI 48202, USA. pkuriak1@hfhs.org

Cancer Control : Journal of the Moffitt Cancer Center
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study.

Blood vessels, thrombosis & hemostasis·2026
Same author

BCL2-Rearrangment-Negative CD23+ Follicle Center Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Biclonal Composite Lymphoma.

Cureus·2025
Same author

Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.

Blood vessels, thrombosis & hemostasis·2025
Same author

Increasing Olanzapine Prescribing for Patients Undergoing Highly Emetogenic Chemotherapy.

JAMA network open·2025
Same author

Infusion Reactions With Alternative Therapies During the National Shortage of Iron Dextran.

European journal of haematology·2024
Same author

Observational cohort study of long-term outcomes of liver transplantation in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same journal

Factors Influencing Advance Care Planning in Oncology: A Qualitative Study of Clinician Perspectives Using the Theoretical Domains Framework.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Tumor Microenvironment: The Kingpin in the Emergence of Resistance to Cancer Therapy.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Validation of the Taiwan Cancer Frailty Tool for Screening and Prognosis in Non-older Patients With Cancer: A Prospective Multicenter Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Improving Breast Cancer Outcomes by Enhanced Activities in Early Detection and Diagnosis: An Umbrella Review and Meta-Analyses of Randomised Controlled Trials in High-Income Contexts With Universal Healthcare Coverage.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same journal

Evaluating A Patient-Led Health Literacy Program for People Living With Metastatic Breast Cancer.

Cancer control : journal of the Moffitt Cancer Center·2026
See all related articles

Targeted therapies, including monoclonal antibodies, offer effective and less toxic treatment options for hematologic malignancies. Further research is needed to optimize their integration into treatment regimens.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Monoclonal antibodies and small molecules represent novel therapeutic strategies for hematologic malignancies.
  • These targeted agents offer new treatment avenues for patients with blood cancers.

Purpose of the Study:

  • To review clinical trials of monoclonal antibody and targeted therapies in hematologic malignancies.
  • To assess the efficacy and safety of these novel treatment approaches.

Main Methods:

  • Systematic review of published clinical trials.
  • Analysis of data from studies involving monoclonal antibodies and other targeted agents.

Main Results:

  • Monoclonal antibodies (native or conjugated) and targeted therapies show therapeutic benefits.

Related Experiment Videos

  • These agents are effective both as monotherapy and in combination with chemotherapy.

    • Conclusions:

    • Targeted therapy is an effective and less toxic approach for hematologic malignancies.
    • Further studies are required to define the optimal role of targeted therapy in treatment protocols.